Intracellular ATP enhancer
AssigneeStaGen Co., Ltd.
InventorNaoyuki Kamatani
Life of this patent
Estimating the term…
Abstract
A problem to be solved by the present invention is to provide a substance having an effect of increasing intracellular ATP and, particular, a potent ATP enhancer far surpassing the increasing effect of inosine alone or a xanthine oxidase/xanthine dehydrogenase inhibitor alone. A human or animal intracellular ATP enhancer comprising a combination of A) and B): A) a xanthine oxidase/xanthine dehydrogenase inhibitor; and B) hypoxanthine, or a compound capable of being converted to hypoxanthine in the body.
Claims11
A method of enhancing intracellular ATP in human or animal, comprising the step of:
- administering to a human or an animal A) and B):
- A) allopurinol or topiroxostat, or a pharmaceutically acceptable salt thereof;
- and
- B) any one or more compounds selected from inosine, inosinic acid, and pharmaceutically acceptable salts thereof.
A method of enhancing intracellular ATP comprising the step of
- administering A) and B) to a patient with hemolytic anemia, ischemic heart disease, heart failure, amyotrophic lateral sclerosis, Parkinson's disease, or ADSL deficiency:
- A) allopurinol or topiroxostat, or a pharmaceutically acceptable salt thereof;
- and
- B) any one or more compounds selected from inosine, inosinic acid, and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.